Kisunla: A New Breakthrough in Alzheimer's Treatment

On July 2nd, 2024, Eli Lilly proudly announced that its investigational anti-Aβ antibody Donanemab (brand name Kisunla) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of early symptomatic Alzheimer's disease in adults, including those with mild cognitive impairment and mild dementia stages of the neurodegenerative disease. This approval marks Kisunla as the second Alzheimer's medication in the U.S. market aimed at slowing the progression of the disease, providing patients with a new treatment option.

The approval of Kisunla was based on the remarkable results from the TRAILBLAZER-ALZ 2 trial. According to data presented by Eli Lilly at the 2023 Alzheimer's Association International Conference (AAIC), donanemab was able to significantly slow the cognitive and functional decline in early-stage Alzheimer's patients, effectively delaying the disease progression. Subgroup analysis revealed that the patients in the earliest stages of the disease benefited the most, with up to a 60% reduction in cognitive and functional decline compared to placebo. Moreover, the benefits were even more pronounced in patients younger than 75 years of age.

Importantly, donanemab treatment significantly reduced amyloid plaque levels in patients regardless of their baseline disease stage, offering new possibilities for disease control.

Eli Lilly highlighted the unique advantages of Kisunla in their approval announcement. Kisunla is the first anti-amyloid drug that allows for treatment discontinuation after plaque clearance, significantly reducing the number of infusions and thereby lowering the overall treatment cost, providing substantial economic benefits to patients.

In contrast, the other market-available medication, Leqembi, developed by Eisai and Biogen, requires biweekly intravenous infusions. Kisunla, on the other hand, utilizes a once-every-four-weeks dosing regimen, offering patients a more convenient treatment option. Regarding pricing, Eli Lilly has set the price of Kisunla at $695.65 per vial, with the total cost depending on the duration of the patient's treatment. Although the annual cost of the Eli Lilly regimen is slightly higher at $32,000 compared to Leqembi's $26,500 in the U.S., Kisunla's unique mechanism of action and more convenient dosing make it a noteworthy new addition to the market.

However, Kisunla faces some challenges as well. Compared to Leqembi, Kisunla's ARIA (Amyloid-Related Imaging Abnormalities) safety profile is considered slightly less favorable. While Leqembi requires four brain MRI scans before infusion, Kisunla necessitates five. Eli Lilly has stated that performing an MRI scan before the second infusion can reduce the incidence of severe ARIA cases by 25%, making the additional MRI scans a necessary measure to ensure patient safety.

Despite this shortcoming, Kisunla's innovations and advantages in the Alzheimer's treatment landscape make it a medication worth the attention of both healthcare providers and patients.